Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Entospletinib in Hepatic Impairment
NCT02521376Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of entospletinib in hematologic malignancy (3 arms), sponsored by Gilead Sciences. Primary endpoints: Area under the concentration-time curve over the dosing interval at Day 5 and Maximum observed plasma concentration at Day 5. Started Nov 2015; status: completed.
02
Drugs
entospletinib
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02521376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521376.